Your browser doesn't support javascript.
Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19.
Aliter, Kholoud F; Al-Horani, Rami A.
  • Aliter KF; Department of Chemistry, School of STEM, Dillard University, New Orleans, LA, 70122, USA.
  • Al-Horani RA; Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, 1 Drexel Drive, New Orleans, LA, 70125-1089, USA. ralhoran@xula.edu.
Cardiovasc Drugs Ther ; 35(2): 195-203, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-737530
Semantic information from SemMedBD (by NLM)
1. argatroban INHIBITS thrombin
Subject
argatroban
Predicate
INHIBITS
Object
thrombin
2. Receptor AFFECTS C0021368
Subject
Receptor
Predicate
AFFECTS
Object
C0021368
3. thrombin AFFECTS Angiogenic Process
Subject
thrombin
Predicate
AFFECTS
Object
Angiogenic Process
4. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
5. Inhibitor PART_OF thrombin
Subject
Inhibitor
Predicate
PART_OF
Object
thrombin
6. Therapeutic procedure PREDISPOSES Drug Interactions
Subject
Therapeutic procedure
Predicate
PREDISPOSES
Object
Drug Interactions
7. argatroban TREATS Borg Category-Ratio 10 Perceived Exertion Score 5
Subject
argatroban
Predicate
TREATS
Object
Borg Category-Ratio 10 Perceived Exertion Score 5
8. argatroban INHIBITS thrombin
Subject
argatroban
Predicate
INHIBITS
Object
thrombin
9. Receptors, Proteinase-Activated AFFECTS Inflammation
Subject
Receptors, Proteinase-Activated
Predicate
AFFECTS
Object
Inflammation
10. thrombin AFFECTS Angiogenic Process
Subject
thrombin
Predicate
AFFECTS
Object
Angiogenic Process
11. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
12. Inhibitor PART_OF thrombin
Subject
Inhibitor
Predicate
PART_OF
Object
thrombin
13. Therapeutic procedure PREDISPOSES Drug Interactions
Subject
Therapeutic procedure
Predicate
PREDISPOSES
Object
Drug Interactions
14. argatroban TREATS Borg Category-Ratio 10 Perceived Exertion Score 5
Subject
argatroban
Predicate
TREATS
Object
Borg Category-Ratio 10 Perceived Exertion Score 5
ABSTRACT
Thrombin is a trypsin-like serine protease with multiple physiological functions. Its role in coagulation and thrombosis is well-established. Nevertheless, thrombin also plays a major role in inflammation by activating protease-activated receptors. In addition, thrombin is also involved in angiogenesis, fibrosis, and viral infections. Considering the pathogenesis of COVID-19 pandemic, thrombin inhibitors may exert multiple potential therapeutic benefits including antithrombotic, anti-inflammatory, and antiviral activities. In this review, we describe the clinical features of COVID-19, the thrombin's roles in various pathologies, and the potential of argatroban in COVID-19 patients. Argatroban is a synthetic, small molecule, direct, competitive, and selective inhibitor of thrombin. It is approved to parenterally prevent and/or treat heparin-induced thrombocytopenia in addition to other thrombotic conditions. Argatroban also possesses anti-inflammatory and antiviral activities and has a well-established pharmacokinetics profile. It also appears to lack a significant risk of drug-drug interactions with therapeutics currently being evaluated for COVID-19. Thus, argatroban presents a substantial promise in treating severe cases of COVID-19; however, this promise is yet to be established in randomized, controlled clinical trials.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Arginine / Pipecolic Acids / Sulfonamides / SARS-CoV-2 / COVID-19 Type of study: Controlled clinical trial / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Cardiovasc Drugs Ther Journal subject: Vascular Diseases / Cardiology / Drug Therapy Year: 2021 Document Type: Article Affiliation country: S10557-020-07066-x

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Arginine / Pipecolic Acids / Sulfonamides / SARS-CoV-2 / COVID-19 Type of study: Controlled clinical trial / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Cardiovasc Drugs Ther Journal subject: Vascular Diseases / Cardiology / Drug Therapy Year: 2021 Document Type: Article Affiliation country: S10557-020-07066-x